Browse > Article
http://dx.doi.org/10.5302/J.ICROS.2004.10.12.1119

Optimized Structured Treatment Interruption for HIV Therapy and Its Performance Analysis on Controllability  

Ko Ji Hyun (Drexel University 의용생체공학부)
Kim Won Hee (한양대학교 전자전기컴퓨터공학부)
Chung Han Byul (한양대학교 전자전기컴퓨터공학부)
Chung Chung Choo (한양대학교 전자전기컴퓨터공학부)
Publication Information
Journal of Institute of Control, Robotics and Systems / v.10, no.12, 2004 , pp. 1119-1126 More about this Journal
Abstract
This paper presents optimized structured treatment interruption to reduce medication and establish long-term immune response against HIV-infection. Understanding HIV-related immune system control enables better HIV therapy without using full­treatments. Discrete regimen and continuous regimen characteristics are compared. Controllability of HIV-related immune system is analyzed for better understanding of optimal control in HIV therapy. Using optimal control provides more effective therapy than the full treatment without interruption in terms of controllability analysis. Case studies indicates that the proposed therapy induces long-erm non-progression while preserving high CD4 T-helper cell count and low virus load in HIV-infected patients.
Keywords
optimal control; STI; HIV; MPC; controllability; dynamic programming;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 R. Zurakowski, A. R. Teel, and D. Wodarz, 'Utilizing alternate target cells in treating HIV infection through scheduled treatment interruptions,' American Control Conference, Boston, pp. 946-951, June 2004
2 S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker, E. Swin, 'Modeling control of HIV infection through structured treatment interruptions with recommendations for experimental protocol,' CRSC Technical Report (CRSC-TR01-27). 2001. (Also at http://www.math.montana.edu/parker.)
3 A. Schwartz, 'Theory and implementation of numerical methods based on Runge-Kutta integration for solving optimal control problems,' Ph.D Dissertation, Univ. of California, Berkeley, 1996
4 D. E. Kirk, 'Optimal Control Theory: An Introduction,' Prentice Hall,1970
5 D. Wodarz, 'Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001   DOI   ScienceOn
6 D. Q. Mayne, J. B. Rawlings, C. V. Rao and P. O. M. Scokaert, 'Constrained model predictive control: Stability and optimality,' Automatica, vol. 36, pp. 789-814, 2000   DOI   ScienceOn
7 J. M. Lee and J. H. Lee, 'Approximate dynamic programming strategies and their applicability for process control: A review and and future directions,' submitted to International Journal of Control, Automation and Systems, May 2004
8 R. F. Stengel, R. Ghigliazza, N. Kulkami and O. Laplace, 'Optimal control of innate immune response,' Optimal Control Applications and Methods, vol. 23, pp. 91-104, January 2002   DOI   ScienceOn
9 M. E. Brandt and G. Chen, 'Feedback control of a biodynamical model of HIV-l,' IEEE Trans. on Biomedical Engineering, vol. 48,pp.754-759,July 2001   DOI   ScienceOn
10 J. J. Kutch and P. Gurfil, 'Optimal control of HIV infection with acontinuously-mutating viral population,' Proceedings of the American Control Conference, vol 5, pp. 4033-4038, Anchorage, May 2002
11 J. A. M. Felippe de Souza, M. A. L. Caetano and T. Yoneyama, 'Analysis of a sub-optimal scheme of drug dosage in the AIDS treatment,' In proceedings of American Control Conference, pp. 1188-1193, Denver, Colorado, June 2003
12 R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' American Control Conference, Denver, pp. 1182-1187, June 2003
13 H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HlV infection: continuous dose control and receding horizon control,' International Journal of Control, Automation and Systems. vol. 1, no. 3, pp. 282-288, September 2003
14 A. M. Jeffrey, X. Xia, and I. K. Craig, 'Controllability analysis of the chemotherapy of HlV/AIDS,' IFAC, 15th Triennial World Congress, Barcelona, Spain, 2002
15 D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999   DOI
16 A. M. Jeffrey, X. Xia, and I. K. Craig, 'When to inititate HIV therapy: a control theoretic approach,' IEEE Trans. On Biomedical Engineering, vol. 50, no 11, pp. 1213-1220, Nov. 2003   DOI   ScienceOn
17 M. A. Nowak and R. M. May, 'Virus dynamics: mathematical principles of immunology and virology,' Oxford University Press, 2000
18 J. S. James, 'Human retroviruses and related infections,' Major U.S. Scientific AIDS Conference, Feb. 1995. [Online]. Available: http://www.aids.org/atn/a-216-01.html
19 D. Wodarz and M. A. Nowak, 'Treatment interruptions,' factsheets, AIDS.org, April 2003. [Online] Available: http://www.aids.org/factSheets/406-Treatment -Interruptions.html
20 J. S. James, 'Treatment interruption; advanced HIV,' Dr. Cal Cohen Interview on Retroviruses Conference (part 2 of 2), April 2003. [Online] Available: http://www.aids.org/atn/a-390-01.html
21 R. F. Stengel, R. Ghigliazza, N. Kulkami and O. Laplace, 'Optimal control of a viral disease,' In proceedings of American Control Conference, vol. 5, pp. 3795-3800, June 2001   DOI
22 R. F. Stengel, R. Ghigliazza and N. Kulkami, 'Optimal enhancement of immune response,' Bioinformatics, vol. 18, pp. 1227-1235, March 2002   DOI   ScienceOn
23 A. S. Perelson and P. W. Nelson, 'Mathematical analysis of HIV-1 dynamics in vivo,' SIAM, vol. 41, no. 1, pp. 3-44, 1999   DOI   ScienceOn
24 S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, 'Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,' AIDS, vol. 14, pp. 2313-2322, 2000   DOI   ScienceOn
25 C. A. Janeway, 'Immunobiology,' Garland Churchill Livingstone, 2001